Workflow
TUS-PHARMA(000590)
icon
Search documents
启迪药业集团股份公司 关于原控股股东所持股份被司法拍卖完成过户登记的公告
登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示: 1、2025年8月11日,经公司向中国证券登记结算公司深圳分公司查询获悉,公司原控股股东启迪科技服 务有限公司(以下简称:"启迪科服")所持公司被司法拍卖的58,606,962股股票已完成过户登记手续。 2、本次过户完成后,公司原控股股东启迪科服已不再持有公司股份,启迪科服及其一致行动人北京华 清投资有限公司(以下简称"华清投资")持有的公司股票总数从63,151,413股下降为4,544,451股,占公 司总股本的比例从26.37%下降至1.90%。湖南赛乐仙持有公司股票数从0股增加为58,606,962股,占公司 总股本比例从0增加为24.47%。 2025年8月6日,公司收到湖南赛乐仙送达的《北京金融法院执行裁定书》,主要内容如下: 3、本次权益变动系启迪科服所持公司股份被司法拍卖所致。本次权益变动不触及要约收购。本次权益 变动完成后,湖南赛乐仙将持有公司24.47%的股份。 一、本次司法拍卖基本情况 详情可查阅公司于2025年7月16日在《 ...
启迪药业集团股份公司关于原控股股东所持股份被司法拍卖完成过户登记的公告
Core Viewpoint - The announcement details the completion of the judicial auction and transfer of shares held by the original controlling shareholder, Tsinghua Tongfang Technology Service Co., Ltd., to Hunan Sailoxian, resulting in a significant change in shareholding structure and control of the company [1][2][3]. Group 1: Judicial Auction Details - On July 15, 2025, Tsinghua Tongfang's 58,606,962 shares were successfully auctioned to Hunan Sailoxian for a total price of 1,007,392,612.46 yuan, representing 24.47% of the company's total share capital [2]. - The transfer of ownership was formalized on August 6, 2025, with the shares being registered under Hunan Sailoxian's name following the court's ruling [3]. Group 2: Shareholding Changes - Following the transfer, Tsinghua Tongfang no longer holds any shares in the company, reducing its total shareholding from 63,151,413 shares (26.37%) to 4,544,451 shares (1.90%) [1]. - Hunan Sailoxian's shareholding increased from 0 to 58,606,962 shares, now constituting 24.47% of the total share capital [1]. Group 3: Impact on Company Control - The change in shareholding does not trigger a mandatory tender offer, but it does indicate a shift in the company's controlling shareholder and actual controller [5]. - The company maintains that this transaction will not affect its independence in terms of business, assets, finance, personnel, or organization from the new controlling shareholder [5].
启迪药业原控股股东所持股份被司法拍卖完成过户登记
Bei Jing Shang Bao· 2025-08-12 13:35
Group 1 - The core point of the article is that Tsinghua Unigroup's controlling stake in Qidi Pharmaceutical has been significantly reduced due to a judicial auction, resulting in a new major shareholder [1] - After the transfer of 58.607 million shares, Tsinghua Unigroup's shareholding in Qidi Pharmaceutical decreased from 26.37% to 1.9% [1] - Hunan Sailoxian has become a major shareholder, holding 24.47% of the total shares after previously holding none [1]
启迪药业(000590) - 启迪药业集团股份公司简式权益变动报告书-启迪科服
2025-08-12 10:33
启迪药业集团股份公司 简式权益变动报告书 上市公司名称:启迪药业集团股份公司 股票上市地点:深圳证券交易所 股票简称:启迪药业 股票代码:000590.SZ 信息披露义务人(一):启迪科技服务有限公司 住所:北京市海淀区中关村东路1号院1号楼A座15层1503 通讯地址:北京市海淀区中关村清华科技园科技大厦A座22层 信息披露义务人(二):北京华清投资有限公司(一致行动人) 住所:北京市海淀区中关村东路1号院8号楼9层南侧 通讯地址:北京市海淀区中关村东路1号院8号楼9层南侧 权益变动性质:股份减少(司法拍卖) 签署日期:2025年8月 信息披露义务人声明 六、本次信息披露义务人持股变化的原因是信息披露义务人持有的启迪药业集团 股份公司58,606,962股股票(限售流通股)被北京金融法院强制拍卖。 七、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏, 并 对其真实性、准确性、完整性承担个别和连带的法律责任。 1 | | 信息披露义务人声明 1 | | --- | --- | | 第一节 | 释义 3 | | 第二节 | 信息披露义务人介绍 4 | | 第三节 | 权益变动目的 7 | | 第 ...
启迪药业(000590) - 关于原控股股东所持股份被司法拍卖完成过户登记的公告
2025-08-12 10:33
证券代码:000590 证券简称:启迪药业 公告编号:2025-027 启迪药业集团股份公司 关于原控股股东所持股份被司法拍卖完成过户登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示: 1、2025年8月11日,经公司向中国证券登记结算公司深圳分公司查询获 悉,公司原控股股东启迪科技服务有限公司(以下简称:"启迪科服")所持 公司被司法拍卖的58,606,962股股票已完成过户登记手续。 2、本次过户完成后,公司原控股股东启迪科服已不再持有公司股份,启迪 科服及其一致行动人北京华清投资有限公司(以下简称"华清投资")持有的公 司股票总数从 63,151,413 股下降为 4,544,451 股,占公司总股本的比例从 26.37% 下降至 1.90%。湖南赛乐仙持有公司股票数从 0 股增加为 58,606,962 股,占公 司总股本比例从 0 增加为 24.47%。 3、本次权益变动系启迪科服所持公司股份被司法拍卖所致。本次权益变动 不触及要约收购。本次权益变动完成后,湖南赛乐仙将持有公司 24.47%的股份。 一、本次司法拍卖基本情况 ...
启迪药业高溢价收购合理性存疑 投服中心呼吁中小股东积极行权
Xin Hua Wang· 2025-08-12 05:47
Core Viewpoint - Qidi Pharmaceutical plans to acquire 55% of Wuhan Mingshi Pharmaceutical for 141.35 million yuan, facing opposition from three directors due to concerns over the target company's weak core competitiveness and high acquisition price [1][2]. Group 1: Target Company Overview - The target company specializes in the research, production, and sales of traditional Chinese medicine and health food, holding three Chinese medicine approvals and 13 health food registrations [2]. - The net profits for the target company were 13.14 million yuan in 2022 and 13.42 million yuan from January to August 2023 [2]. Group 2: Concerns from Directors and Analysts - Three out of seven directors, including the vice chairman and an independent director, voted against the acquisition, citing the target company's lack of flagship products and weak core competitiveness [2]. - The target company's valuation of 260 million yuan represents a 400.72% increase, which analysts believe does not align with its core competitiveness [2][3]. Group 3: Performance Commitments and Industry Challenges - The target company has made performance commitments for net profits of no less than 22 million yuan, 25.3 million yuan, and 26.4 million yuan from 2024 to 2026, which represents an 87% increase compared to its 2022 net profit [2]. - Analysts express skepticism about the target company's ability to meet these commitments due to declining product prices, a slowdown in the health food industry, and rising raw material costs [3]. Group 4: Risks Associated with the Acquisition - The acquisition announcement did not adequately disclose potential risks, including the risk of performance commitment failure, as the commitment is backed by two individual shareholders without sufficient guarantees [4]. - There is a risk of goodwill impairment due to the high acquisition price compared to the target company's book value, which could impact the acquirer's financial health [4]. - The acquirer's current financial situation raises concerns about its ability to support the acquisition cost and other ongoing investments, with a reported cash flow deficit and declining profitability [5].
启迪药业控制权将变更;硕世生物上半年净利润同比降逾八成丨医药早参
Mei Ri Jing Ji Xin Wen· 2025-08-10 23:21
Group 1 - Tsinghua Unigroup's control will change as Hunan Sailuxian will acquire approximately 58.61 million shares from its controlling shareholder, Tsinghua Technology Service Co., Ltd, leading to a shift in control of Tsinghua Unigroup [1] - The new controlling shareholder will need to stabilize the company's operations amidst industry consolidation, and investors should pay attention to future asset integration and the new shareholder's resource injection capabilities, with potential short-term stock price volatility [1] Group 2 - Shuoshi Bio reported a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year, primarily due to the deepening of centralized procurement in the in vitro diagnostic industry and an increase in the VAT rate to 13% [2] - The decline in net profit is attributed to pressure on product prices from industry procurement, a significant drop in gross margin, and a 13.11% reduction in R&D investment, which may weaken long-term competitiveness [2] Group 3 - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech, received FDA approval to conduct Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic cancer, marking a significant step in the internationalization of innovative drugs [3] - The drug's dual advantages of immune modulation and precise targeting position it competitively in the global market, with the potential to fill a treatment gap for thymic cancer if subsequent data is positive [3] Group 4 - Junshi Biosciences announced that the National Medical Products Administration has accepted the application for the 13th indication of its PD-1 monoclonal antibody, Toripalimab, for use in combination with HER2 ADC for patients with locally advanced or metastatic urothelial carcinoma expressing HER2 [4] - This combination is expected to further strengthen Junshi's differentiated positioning in the PD-1 market and enhance collaboration with Rongchang Bio on ADC development [4]
启迪药业控制权拟发生变更
Bei Jing Shang Bao· 2025-08-10 03:30
Core Viewpoint - Tsinghua Tongfang Pharmaceutical (启迪药业) is undergoing a significant change in its ownership structure due to a judicial auction of shares held by its controlling shareholder, Tsinghua Tongfang Technology Service Co., Ltd. (启迪科服), which will result in a new major shareholder, Hunan Sailuxian Management Consulting Partnership (湖南赛乐仙) [1] Group 1 - On August 6, Tsinghua Tongfang Pharmaceutical received a court ruling from the Beijing Financial Court regarding the transfer of 58.607 million shares to Hunan Sailuxian [1] - The share transfer represents 24.47% of Tsinghua Tongfang Pharmaceutical's total shares, indicating a substantial shift in ownership [1] - Following this transfer, Tsinghua Tongfang Technology Service Co., Ltd. will no longer hold any shares in Tsinghua Tongfang Pharmaceutical, leading to a change in control and potential impacts on corporate governance [1]
000590,控制权拟变更
Core Viewpoint - The announcement by Qidi Pharmaceutical indicates a significant change in its shareholding structure, with Hunan Sailuxian acquiring a substantial stake, leading to a shift in control of the company [1][2]. Group 1: Shareholding Changes - Qidi Pharmaceutical announced that Hunan Sailuxian will acquire 58.607 million shares from Qidi Technology Service Co., resulting in a decrease of Qidi Technology's holdings from 63.151 million shares to 4.544 million shares, reducing its ownership percentage from 26.37% to 1.90% [1][3]. - Following this transaction, Hunan Sailuxian will hold 24.47% of Qidi Pharmaceutical's shares, making it the largest shareholder, surpassing Qidi Technology Service [2][5]. Group 2: Financial Details - The shares were sold at an average price of 17.19 yuan per share, totaling approximately 1.007 billion yuan for the transaction [5]. - As of August 8, Qidi Pharmaceutical's market capitalization was approximately 2.85 billion yuan, with a closing price of 11.90 yuan per share [6]. Group 3: Company Background - Qidi Pharmaceutical, established in 1956, is recognized as Hunan Province's first pharmaceutical listed company and has notable brands such as "Guhan" [5].
启迪药业控制权将变更 湖南赛乐仙有望带来新动能
Zheng Quan Ri Bao Wang· 2025-08-09 04:11
Group 1 - Qidi Pharmaceutical has undergone a significant change in control, with Hunan Sailuxian acquiring approximately 58.61 million shares, resulting in a shift from Qidi Technology Service Co., Ltd. holding 26.37% to 1.90% of the total shares [1] - Hunan Sailuxian will hold 24.47% of Qidi Pharmaceutical's shares, which is expected to bring new momentum to the company's development [1] - Qidi Pharmaceutical's operations will remain unaffected by this equity change, and the company is preparing to launch several new products that could benefit from strong sales channel support [1] Group 2 - Hunan Hengchang Pharmaceutical, a key player in the biopharmaceutical sector in Hunan Province, has transitioned from a "small brand attached to large manufacturers" model to a "brand exclusive" model, enhancing its competitive edge [2] - The company operates through four logistics bases and serves 200,000 small and medium-sized pharmacies and grassroots medical institutions, with an annual shipment volume exceeding 7.5 billion yuan [2] - Hengchang Pharmaceutical is investing over 40 million yuan in the Zhuangyuan Pharmaceutical R&D Center project, focusing on the development of traditional Chinese medicine and chemical drug formulations [2] Group 3 - Experts suggest that Qidi Pharmaceutical has struggled to improve its operating performance, indicating a lack of internal motivation that may require external support [3] - The integration of Hunan Sailuxian's sales channels and supply chain with Qidi Pharmaceutical's quality products could enhance the company's internal dynamics and improve operational performance [3]